Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Animal Study Of Rexahn's Serdaxin™ Shows Drug's Promise To Treat Anxiety And Depression With Minimal Side Effects
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced the results of a wide-ranging animal study offering more evidence that Serdaxin™ may be an effective therapeutic for the treatment of anxiety disorders in humans. Serdaxin is Rexahn"s leading anxiety and depression drug candidate, and is currently in Phase II clinical trials.

Democrat Bill, FTC Examine Ways To Drive Down Health Care Costs
A bill introduced Wednesday in the House would create an artificial joints database to root out bad practices and unnecessary surgeries, The New York Times reports. "The bill, co-sponsored by (Democrats) Bill Pascrell Jr. of New Jersey and Lloyd Doggett of Texas, would establish a government-backed registry to track patients" results over time and help detect ineffective surgical practices and faulty devices. Patient registries, in areas like orthopedics, are expected to play an important role in "comparative effectiveness" reviews that the Obama administration hopes will help identify which medical procedures and products work best."
News of the day
Connecticut Health Department Urges Food Safety When Grilling Outdoors
Summer is the season for sizzling - steaks, chicken, ribs, veggie kabobs and much more. The Connecticut Department of Public Health reminds everyone that food safety is essential when grilling outdoors and offers tips to ensure that family barbecues and backyard picnics remain fun, healthy outings.
Sexual Health

ImmunoVaccine Technologies Partners With FIT Biotech To Advance A Therapeutic HIV Vaccine

ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, announced a research partnership with FIT Biotech, a Finland-based , clinical stage company that develops DNA vaccines. This research will formulate FIT Biotech"s GTU(R) MultiHIV DNA plasmid with IVT"s DepoVax(TM) vaccine delivery system to advance a therapeutic HIV vaccine. "DepoVax(TM) will act as a vector to deliver FIT Biotech"s GTU(R) MultiHIV DNA vaccine and our goal is to develop a more sophisticated and efficient HIV vaccine candidate," commented Dr. Marc Mansour, Vice President R&D at IVT. The development of an HIV vaccine is complicated by the ability of the virus to mutate rapidly. FIT Biotech has addressed this challenge by designing a synthetic DNA plasmid, known as GTU(R) MultiHIV that covers the antigenic variability within HIV strains. GTU(R) MultiHIV and is comprised of the multi-epitope/multivalent HIV antigens. As FIT Biotech"s lead vaccine candidate, GTU(R) MultiHIV has the potential to trigger an immune response that slows the progression of HIV in infected individuals. IVT"s pre-clinical research demonstrates that DepoVax(TM) effectively delivers DNA plasmids into draining lymph nodes with as little as one dose. The DepoVax(TM) platform uses liposomes to encapsulate a target antigen, like GTU(R) MultiHIV, and adjuvant. DepoVax(TM) also relies on a hydrophobic carrier to create a depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity. This pre-clinical research partnership will combine the complementary technologies of DepoVax(TM) and GTU(R) MultiHIV. Both IVT and FIT Biotech will examine the novel vaccine"s capabilities of inducing cell-mediated and humoral immunity against HIV virus. "By testing DepoVax(TM) in combination with GTU(R) MultiHIV plasmid, we are working towards developing a superior vaccine candidate for therapeutic use against HIV and AIDS," said Kalevi Reijonen, President and CEO at FIT Biotech. The WHO reports that 33 million people are living with HIV and the epidemic is rapidly expanding with 2.7 million people newly infected in 2007. Nearly all of them will develop AIDS-related complications, creating an urgent need for effective HIV therapeutic vaccines. Therapeutic vaccination offers the most hope for HIV infected individuals because it maintains a low viral load and has the potential to modify the course of the infection and its progression towards the AIDS disease. ImmunoVaccine Technologies Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009